Intra-Cellular Therapies Prices $114 Million Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Intra-Cellular Therapies (ITCI) PT Raised to $29 at Cowen
March 9, 2015 9:09 AM EDTCowen analyst Ritu Baral reiterated an Outperform rating and boosted the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $29.00 (from $24.00) following last'weeks conference.
Baral commented, "We are increasing our target from $24 to $29 based on positive from our survey and panel KOLs... More
Intra-Cellular Therapies (ITCI) Prices 4.75M Offering at $24/Share
March 6, 2015 6:14 AM ESTIntra-Cellular Therapies (Nasdaq: ITCI) announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $24.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to... More
